Activated T Cells and Soluble Molecules in the Portal Venous Blood of Patients with Cholestatic and Hepatitis C Virus-Positive Liver Cirrhosis. Possible Promotion of Fas/FasL-Mediated Apoptosis in the Bile-Duct Cells and Hepatocyte Injury
Free accessResearch articleFirst published online June, 2003
Activated T Cells and Soluble Molecules in the Portal Venous Blood of Patients with Cholestatic and Hepatitis C Virus-Positive Liver Cirrhosis. Possible Promotion of Fas/FasL-Mediated Apoptosis in the Bile-Duct Cells and Hepatocyte Injury
We investigated the immune responses of patients with cholestatic and hepatitis C virus-positive (HCV-positive) liver cirrhosis by analysing T-cell subsets and cytokine levels in the portal and peripheral veins, using flow cytometry and enzyme-linked immunosorbent assay. In cholestatic liver cirrhosis, the proportion of natural-killer (NK) T cells and interleukin (IL) 6 and IL-18 levels in the portal venous blood were significantly higher than those in the peripheral venous blood. In HCV-positive liver cirrhosis, the proportions of NK T cells and Fas+ T cells and IL-6 and soluble Fas levels in the portal venous blood were significantly higher than those in the peripheral venous blood. These results suggest that in these diseases, activated T cells and soluble molecules in portal venous blood may promote Fas/FasL-mediated apoptosis of the bile-duct cells and hepatocytes, and contribute to the deterioration in liver function as an inevitable result of positive feedback.
BalistreriWFGrandRHoofnagleJH: Biliary atresia. Current concepts and research directions. Summary of a symposium. Hepatology1996; 23: 1682–1692.
3.
ParkWHKimSPParkKK: Electron microscopic study of the liver with biliary atresia and neonatal hepatitis. J Pediatr Surg1996; 31: 367–374.
4.
YagiTIwagakiHUrushiharaNKobashiKNakaoAMatsukawaH: Participation of IL-18 in human cholestatic cirrhosis and acute rejection. Analysis in living donor liver transplantation. Transplant Proc2001; 33: 421–425.
5.
RosenHRMartinP: Hepatitis C infection in patients undergoing liver transplantation. Transplantation1998; 66: 1612–1616.
6.
CharltonMSeabergEWiesnerREverhartJZettermanRLakeJ: Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology1998; 28: 823–830.
7.
DesmetVJ: Congenital diseases of intrahepatic bile ducts. Variations on the theme ‘ductal plate malformation’. Hepatology1992; 16: 1069–1083.
8.
TanCEDriverMHowardER: Extrahepatic biliary atresia. A first-trimester event? Clues from light microscopy and immunohistochemistry. J Pediatr Surg1994; 29: 808–814.
9.
MoreckiRGlaserJHChoS: Biliary atresia and reovirus type 3 infection. N Engl J Med1982; 307: 481–484.
10.
De MariaRTestiR: Fas-FasL interactions. A common pathogenetic mechanism in organ-specific autoimmunity. Immunol Today1998; 19: 121–125.
11.
ChinnaiyanAMO'RourkeKTewariMDixitVM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell1995; 81: 505–512.
12.
GrahamAMDollingerMMHowieSEMHarrisonDJ: Bile duct cells in primary biliary cirrhosis are primed for apoptosis. Eur J Gastroenterol Hepatol1998; 10: 553–557.
13.
StraterJMollerP: Pathogenesis of primary biliary cirrhosis. CD95-induced apoptosis at last?Eur J Gastroenterol Hepatol1998; 10: 539–541.
14.
DienesHPLohseAWGerkenGSchirmacherPGallatiHLohrHF: Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. Virchows Arch1997; 431: 119–124.
15.
HiramatsuNHayashiNKatayamaKMochizukiKKawanishiYKasaharaA: Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology1994; 19: 1354–1359.
16.
GallePRHofmannWJWalczakHSchallerHOttoGStremmelW: Involvement for the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med1995; 182: 1223–1230.
17.
PiazzollaGTortorellaCFioreGSerroneMCaccettaLJirilloE: Immunoresponsiveness in chronic hepatitis C patients. Correlation between tissue and serum findings. Immunopharmacol Immunotoxicol1998; 20: 337–354.
18.
GavrieliYShermanYBen-SassonSA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol1992; 119: 493–501.
19.
OgasawaraJWatanabe-FukunagaRAdachiMMatsuzawaAKasugaiTKitamuraY: Lethal effect of the anti-Fas antibody in mice. Nature1993; 364: 806–809.
20.
OkazakiMHinoKFujiiKKobayashiNOkitaK: Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig Dis Sci1996; 41: 2453–2458.
21.
NakanumaYOhtaGKonoNKobayashiKKatoY: Electron microscopic observation of destruction of biliary epithelium in primary biliary cirrhosis. Liver1983; 3: 238–248.
22.
KurokiTSekiSLkawakitaNNakataniKHisaTKitadaT: Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis. Virchows Arch1996; 429: 119–129.
23.
Watanabe-FukunagaRBrannanCICopelandNGJenkinsNANagataS: Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature1992; 356: 314–317.
24.
BannaiMKawamuraTNaitoTKameyamaHAbeTKawamuraH: Abundance of unconventional CD8+ natural killer T cells in the large intestine. Eur J Immunol2001; 31: 3361–3369.
25.
IshigakiMNishimuraHNaikiYYoshiokaKKawanoTTanakaY: The roles of intrahepatic Va14+NK1.1+ T cells for liver injury induced by Salmonella infection in mice. Hepatology1999; 29: 1799–1808.
26.
KanekoYHaradaMKawanoTYamashitaMShibataYGejyoF: Augmentation of Va14 NKT cell-mediated cytotoxicity by interleukin-4 in an autocrine mechanism resulting in the development of Concanavalin A-induced hepatitis. J Exp Med2000; 191: 105–114.
27.
WilsonSBKentSCPattonKTOrbanTJacksonRAExleyM: Extreme Th1 bias of invariant Va24JaQ T cells in type 1 diabetes. Nature1998; 391: 177–181.
28.
SumidaTSakamotoAMurataHMakinoYTakahashiHYoshidaS: Selective reduction of T cells bearing invariant Va24JaQ antigen receptor in patients with systemic sclerosis. J Exp Med1995; 182: 1163–1168.
29.
KawanoTCuiJKoezukaYTouraIKanekoYSatoH: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Va14 NKT cells. Proc Natl Acad Sci U S A1998; 95: 5690–5693.
30.
TagawaYSekikawaKIwakuraY: Suppression of concanavalin A-induced hepatitis in IFN-gamma(−/−) mice, but not in TNF-alpha(−/−) mice: role for IFN-gamma in activating apoptosis of hepatocytes. J Immunol1997; 159: 1418–1428.
31.
TagawaYKakutaSIwakuraY: Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis. Eur J Immunol1998; 28: 4105–4113.
32.
SeinoKKayagakiNTakedaKFukaoKOkumuraKYagitaH: Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology1997; 113: 1315–1322.
33.
WatanabeYMoritaMAkaikeT: Concanavalin A induces perforin-mediated but not Fas-mediated hepatic injury. Hepatology1996; 24: 702–710.
34.
KustersSGantnerFKunstleGTiegsG: Interferon-gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology1996; 111: 462–471.
35.
MizuharaHO'NeilESekiNOgawaTKusunokiCOtsukaK: T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin-6. J Exp Med1994; 179: 1529–1537.
36.
ToyabeSSekiSIiaiTTakedaKShiraiKWatanabeH: Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. J Immunol1997; 159: 1537–1542.
37.
GantnerFLeistMLohseAWGermannPGTiegsG: Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology1995; 21: 190–198.
38.
GantnerFLeistMKustersSVogtKVolkHDTiegsG: T cell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release. Exp Cell Res1996; 229: 137–146.
39.
KustersSTiegsGAlexopoulouLPasparakisMDouniEKunstleG: In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol1997; 27: 2870–2875.
40.
KsontiniRColagiovanniDBJosephsMDEdwardsCKIIITannahillCLSolorzanoCC: Disparate roles for TNF-α and Fas ligand in concanavalin A-induced hepatitis. J Immunol1998; 160: 4082–4089.
41.
MarianiSMMatibaBBaumlerCKrammerPH: Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol1995; 25: 2303–2307.
42.
CascinoIFucciGPapoffGRubertiG: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol1995; 154: 2706–2713.
43.
TanakaNSudaTHazeKNakamuraNSatoKKimuraF: Fas ligand in human serum. Nat Med1996; 2: 317–322.
44.
TaiebJMathurinPPoynardTGougerot-PocidaloMAChollet-MartinS: Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet1998; 351: 1930–1931.
CamargoCAJrMaddenJFGaoWSelvanRSClavienPA: Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology1997; 26: 1513–1520.
47.
PetersMBlinnGJostockTSchirmacherPMeyer zum BuschenfeldeKHGallePR: Combined interleukin-6 and soluble interleukin-6 receptor accelerates liver regeneration. Gastroenterology2000; 119: 1663–1671.
48.
DaoTOhashiKKayanoTKurimotoMOkamuraH: Interferon-γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol1996; 173: 230–235.
49.
OkamuraHTsutsuiHKomatsuTYutsudoMHakuraATanimotoT: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature1995; 378: 88–91.
50.
StollSMullerGKurimotoMSalogaJTanimotoTYamauchiH: Production of IL-18 (IFN-γ-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol1997; 159: 298–302.
51.
StollSJonuleitHSchmittEMullerGYamauchiHKurimotoM: Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC). DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol1998; 28: 3231–3239.
52.
ContiBJahngJWTintiCSonJHJohTH: Induction of interferon-γ-inducing factor in the adrenal cortex. J Biol Chem1997; 272: 2035–2037.
53.
ContiBParkLCCalingasanNYKimYKimHBaeY: Cultures of astrocytes and microglia express interleukin 18. Brain Res Mol Brain Res1999; 67: 46–52.
54.
UrushiharaNIwagakiHYagiTKohkaHKobashiKMorimotoY: Elevation of serum interleukin-18 levels and activation of Kupffer cells in biliary atresia. J Pediatr Surg2000; 35: 446–449.
